19:32 , Jan 20, 2017 |  BC Week In Review  |  Company News

APT Therapeutics, AZ deal

The companies partnered to develop APT's APT102. APT will receive an upfront payment and is eligible for development milestones. AstraZeneca, which has an option to acquire the product, will fund trials of APT102 to treat...
07:00 , Sep 11, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Thrombosis Ectonucleoside triphosphate diphosphohydrolase 3 (ENTPD3; CD39L3) In vitro and canine studies suggest engineered ENTPD3 can...
07:00 , May 10, 2004 |  BioCentury  |  Finance

Midwest work ethic

Midwest work ethic Company Location Round Proposed amt ($M) Focus Notes APT St. Louis, Mo. B $8.0 Stroke Hopes the proceeds will provide about two years of runway and allow it to...